HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of DAGLβ as a therapeutic target for pain in sickle cell disease.

Abstract
Sickle cell disease (SCD) is the most common inherited disease. Pain is a key morbidity of SCD and opioids are the main treatment but their side effects emphasize the need for new analgesic approaches. Humanized transgenic mouse models have been instructive in understanding the pathobiology of SCD and mechanisms of pain. Homozygous (HbSS) Berkley mice express >99% human sickle hemoglobin and several features of clinical SCD including hyperalgesia. Previously, we reported that the endocannabinoid 2-arachidonoylglycerol (2-AG) is a precursor of the pro-nociceptive mediator prostaglandin E2-glyceryl ester (PGE2-G) which contributes to hyperalgesia in SCD. We now demonstrate the causal role of 2-AG in hyperalgesia in sickle mice. Hyperalgesia in HbSS mice correlated with elevated levels of 2-AG in plasma, its synthesizing enzyme diacylglycerol lipase β (DAGLβ) in blood cells, and with elevated levels of PGE2 and PGE2-G, pronociceptive derivatives of 2-AG. A single intravenous injection of 2-AG produced hyperalgesia in non-hyperalgesic HbSS mice, but not in control (HbAA) mice expressing normal human HbA. JZL184, an inhibitor of 2-AG hydrolysis, also produced hyperalgesia in non-hyperalgesic HbSS or hemizygous (HbAS) mice, but did not influence hyperalgesia in hyperalgesic HbSS mice. Systemic and intraplantar administration of KT109, an inhibitor of DAGLβ, decreased mechanical and heat hyperalgesia in HbSS mice. The decrease in hyperalgesia was accompanied by reductions in 2-AG, PGE2 and PGE2-G in the blood. These results indicate that maintaining the physiological level of 2-AG in the blood by targeting DAGLβ may be a novel and effective approach to treat pain in SCD.
AuthorsIryna A Khasabova, Jacob Gable, Malcolm Johns, Sergey G Khasabov, Alexander E Kalyuzhny, Mikhail Y Golovko, Svetlana A Golovko, Stacy Kiven, Kalpna Gupta, Virginia S Seybold, Donald A Simone
JournalHaematologica (Haematologica) Vol. 108 Issue 3 Pg. 859-869 (03 01 2023) ISSN: 1592-8721 [Electronic] Italy
PMID35615929 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Dinoprostone
  • Hemoglobin, Sickle
Topics
  • Mice
  • Humans
  • Animals
  • Hyperalgesia (drug therapy, etiology)
  • Dinoprostone
  • Pain (drug therapy, etiology)
  • Mice, Transgenic
  • Anemia, Sickle Cell (complications, drug therapy)
  • Hemoglobin, Sickle

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: